YONDELIS

This brand name is authorized in Austria, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug YONDELIS contains one active pharmaceutical ingredient (API):

1 Trabectedin
UNII ID0YZQ2TCP - TRABECTEDIN

Trabectedin binds to the minor groove of deoxyribonucleic acid (DNA), bending the helix to the major groove. This binding to DNA triggers a cascade of events affecting several transcription factors, DNA binding proteins, and DNA repair pathways, resulting in perturbation of the cell cycle. Trabectedin has been shown to exert antiproliferative in vitro and in vivo activity against a range of human tumour cell lines and experimental tumours, including malignancies such as sarcoma, breast, non-small cell lung, ovarian and melanoma.

Read about Trabectedin

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
YONDELIS Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01CX01 Trabectedin L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CX Other plant alkaloids and natural products
Discover more medicines within L01CX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02351528
Country: EE Ravimiamet Identifier(s): 1327317, 1327328, 1847796
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 07417001, 07417002
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 015532, 015598
Country: FR Base de données publique des médicaments Identifier(s): 60457338, 66602114
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 155482, 155485
Country: HK Department of Health Drug Office Identifier(s): 59078
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 6626
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291431D1027, 4291431D2023
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1029593, 1029594
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 220M2009
Country: NL Z-Index G-Standaard, PRK Identifier(s): 107654, 107662
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100189891, 100313397
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W52365001, W52366001
Country: SG Health Sciences Authority Identifier(s): 13661P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699650772737
Country: US FDA, National Drug Code Identifier(s): 59676-610
Country: ZA Health Products Regulatory Authority Identifier(s): 43/26/0557

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.